Certa Therapeutics’ FT011 Gains the EMA’s Orphan Drug Designation to Treat Systemic Sclerosis
Shots:
- The EMA has granted orphan drug designation to FT011 for treating Systemic Sclerosis (SSc). It has been designated with the US FDA’s ODD & FTD for the same
- FT011 depicted favorable effectiveness across in vitro & in vivo inflammatory and fibrotic disease models with its P-I & P-IIa showing favorable efficacy, safety & PK. Certa plans a P-IIb confirmatory study and is developing biomarkers & gene signatures for identifying patients, likely to respond to fibrosis treatment
- FT011 (oral) is an FIC therapy that works by targeting GPR68, a membrane GPCR receptor, responsible for fibrosis
Ref: Globenewswire | Image: Certa Therapeutics
Related News:- Certa Therapeutics’ FT011 Receives the US FDA’s Fast Track Designation for Treating Systemic Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
